65,437 trials
Obesity
Primary: Adiponectin — -0.71; -7.52 µg/mL
Hepatitis C, Chronic
Primary: Percentage of Participants With Relapse At 24 Weeks After the End Of Treatment (EOT) — 13.65 Percentage of participants
Plaque Psoriasis · Psoriasis
Primary: Percentage of Participants Achieving a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 24 — 78.2; 59.9 Percentage of participants…
Hepatitis C, Chronic
Primary: Number of Participants Who Completed Treatment With PegIFN-2b/Ribavirin — 56; 150 participants
Respiratory Syncytial Virus Infection
Primary: Number of Hospital Admissions by Respiratory Syncytial Virus Infection — 2 participants
Pain
Primary: Pain Scores Assessed by Neonatal Facial Action — 14; 18; 30; 44 Percentage of time — p=< 0.05
Gastric Cancer
Primary: Median Survival — 8.6; 7.9 Months — p=0.1983
Hepatitis b
Primary: Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders — 394; 371; 180 participants
Influenza
Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) — 2; 2; 1; 0 Participants
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break-Up Time (TFBUT) — 0.7; 0.6 Seconds
Lymphoma, Follicular
Primary: Area Under the Curve (AUC) at 0 to 120, 0 to 168, and 0 to Infinity Hours — 1.04; 1.18; 1.39 %ID.h/mL
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Nasopharyngeal Carriage of Streptococcus Pneumoniae — 12.5; 7.2; 16.6; 9.3 percentage of participants
Psoriasis
Primary: Change From Randomization in PASI Score to Week 24 (Week 18 of Etanercept Monotherapy/Placebo) — 2.9; -1.8 scores on a scale — p=<0.001
Colorectal Neoplasms
Primary: Progression Free Survival (PFS) — 5.72; 6.87; 7.59; 6.44 Months — p=0.8268
Infection
Primary: Colonization at Day 1 Swab — 466; 396; 605; 239 Participants